K562 Cells Were Untreated Control Or Treated With 40nm Rapamycin R

K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
K562 cells were untreated (control) or treated with 40nM rapamycin (R ...
Jurkat (A) and K562 (B) cells were untreated (control) or treated 80nM ...
Jurkat (A) and K562 (B) cells were untreated (control) or treated 80nM ...
(A) K562 cells were treated with or without (control) 10 nM ACM, 2 µM ...
(A) K562 cells were treated with or without (control) 10 nM ACM, 2 µM ...
(A) K562 cells were nucleofected with either control or PTBP1-specific ...
(A) K562 cells were nucleofected with either control or PTBP1-specific ...
(A) V-K562 and B-K562 cells were mock-treated or treated with 100 nM ...
(A) V-K562 and B-K562 cells were mock-treated or treated with 100 nM ...
K562 cells were treated with 2-chromatin complexes were IP with the ...
K562 cells were treated with 2-chromatin complexes were IP with the ...
(A) K562 cells were treated with imatinib with 1µM for 24 hr and the ...
(A) K562 cells were treated with imatinib with 1µM for 24 hr and the ...
Western blot analysis: (A) K562 cells were treated with compound 3d for ...
Western blot analysis: (A) K562 cells were treated with compound 3d for ...
A. K562 (K562-S) and K562-R leukemic cells were treated with 9nM ...
A. K562 (K562-S) and K562-R leukemic cells were treated with 9nM ...
(A) K562 cells were treated with the indicated concentrations of human ...
(A) K562 cells were treated with the indicated concentrations of human ...
K562 cells were treated with increasing concentrations of tyrosine ...
K562 cells were treated with increasing concentrations of tyrosine ...
K562 cells treated with curcumin were arrested in G2/M2 phase. A) A ...
K562 cells treated with curcumin were arrested in G2/M2 phase. A) A ...
The K562 cells were incubated for 48 h without lycopene or with ...
The K562 cells were incubated for 48 h without lycopene or with ...
Cell survival of transfected K562 cells treated with OA. (a) K562 cells ...
Cell survival of transfected K562 cells treated with OA. (a) K562 cells ...
(A) K562 cells were treated as indicated for different time periods and ...
(A) K562 cells were treated as indicated for different time periods and ...
(A) K562 cells were treated as indicated for varying time periods and ...
(A) K562 cells were treated as indicated for varying time periods and ...
Megakaryocytes produced pro-survival exosomes. K562 cells were treated ...
Megakaryocytes produced pro-survival exosomes. K562 cells were treated ...
(A) K562 cells were treated as indicated for different time periods and ...
(A) K562 cells were treated as indicated for different time periods and ...
K562 target cells were incubated with PBMCs (effector cells), that were ...
K562 target cells were incubated with PBMCs (effector cells), that were ...
(A) K562 cells treated with the indicated doses (in µM) of imatinib for ...
(A) K562 cells treated with the indicated doses (in µM) of imatinib for ...
(a) cell cycle analysis of the K562 cells treated with 4-Mc. the cells ...
(a) cell cycle analysis of the K562 cells treated with 4-Mc. the cells ...
Cell cycle analysis of K562 and HEL cells treated with 6-MITC, I7447 ...
Cell cycle analysis of K562 and HEL cells treated with 6-MITC, I7447 ...
K562 target cells were incubated with PBMCs (effector cells), that were ...
K562 target cells were incubated with PBMCs (effector cells), that were ...
(a) cell cycle analysis of the K562 cells treated with 4-Mc. the cells ...
(a) cell cycle analysis of the K562 cells treated with 4-Mc. the cells ...
(A) K562 cells were exposed to 5 nM PSI for 18 h either alone or in ...
(A) K562 cells were exposed to 5 nM PSI for 18 h either alone or in ...
Curve obtained from cell cycle analysis of K562 cells treated with 100 ...
Curve obtained from cell cycle analysis of K562 cells treated with 100 ...
Flow cytometry plots of K562 cells: (A) untreated cells (control); (B ...
Flow cytometry plots of K562 cells: (A) untreated cells (control); (B ...
A. K562 leukemic cells were plated in 75cm2 flasks (2 x 106 cells/30 ...
A. K562 leukemic cells were plated in 75cm2 flasks (2 x 106 cells/30 ...
(A) K562 cells were cultured at a concentration of 8×104/mL in the ...
(A) K562 cells were cultured at a concentration of 8×104/mL in the ...
| Differential gene expression of treated and untreated K562 cell line ...
| Differential gene expression of treated and untreated K562 cell line ...
Mitochondrial membrane potential of (a) untreated and (b) treated K562 ...
Mitochondrial membrane potential of (a) untreated and (b) treated K562 ...
(A) K562 cells (300,000 cells/ml) were maintained in absence (lane +FN ...
(A) K562 cells (300,000 cells/ml) were maintained in absence (lane +FN ...

Loading image details...

Source
Dimensions